PROF Profound Medical Corporation

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board applicable to the preparation of interim condensed consolidated financial statements, including International Accounting Standards 34, Interim Financial Reporting.

“This quarter was highlighted by the American Medical Association’s establishment of three new Current Procedural Terminology, or CPT®, Category 1 codes specific to the TULSA procedure, which is a critical milestone for the broader adoption of the technology to treat prostate diseases in the United States,” said Arun Menawat, Profound’s CEO and Chairman. “In addition, we saw a 38% increase in recurring revenue over Q2-2022, marking the fifth consecutive quarter of recurring revenue growth. For the remainder of 2023, we expect to see an increased pace of U.S. TULSA adoption, driven by a continuing, if not accelerating, trend of recurring revenue growth, as well as the addition of several new sites to our installed base of TULSA-PRO® systems.”

Summary Second Quarter 2023 Results

For the quarter ended June 30, 2023, the Company recorded revenue of approximately $1.6 million, with the full amount coming from recurring revenue, which consists of the sale of TULSA-PRO® consumables, lease of medical devices, procedures and services associated with extended warranties. This compares to revenue of approximately $2.0 million in the same three-month period a year ago, which included $1.2 million in recurring revenue and $864,000 from the one-time sale of capital equipment in international markets.

Total operating expenses, which consist of research and development (“R&D”), general and administrative (“G&A”), and selling and distribution (“S&D”) expenses, were approximately $7.5 million in the second quarter of 2023, a 14% decrease from approximately $8.7 million in the second quarter of 2022.  

Expenditures for R&D for the three months ended June 30, 2023 were approximately $3.2 million, a decrease of 14% compared with approximately $3.7 million in the three months ended June 30, 2022, primarily due to: lower headcount and reimbursement of workforce costs associated with a research project; a decrease in share based compensation due to fewer awards granted for employees; decreases in other expenses because of lower office supplies purchased; and lower amortization expenses due to intangible assets associated with the Sonalleve® brand and technology being fully amortized. Partially offsetting these amounts was an increase in clinical trial costs associated with the CAPTAIN trial treatments and recruitment efforts.

G&A expenses for the 2023 second quarter decreased by 21% to approximately $2.1 million, compared with approximately $2.6 million in the same period in 2022, due primarily to lower salaries and benefits, decreased software expenses, and decreased license costs for enterprise resource planning and customer relationship management software. These were partially offset by increased insurance costs.

Second quarter 2023 S&D expenses decreased by 6% to approximately $2.3 million, compared with $2.4 million in the second quarter of 2022. This was driven lower salaries, benefits and share based compensation. Partially offsetting these amounts was an increase in consulting fees, marketing, travel and other expenses due to increased in-person conferences, customer meetings, release of patient videos, marketing materials and overall increase to general expenses.

Net finance costs for the three months ended June 30, 2023 were approximately $884,000, compared with approximate net finance income of $1.9 million in the three months ended June 30, 2022.

Second quarter 2023 net loss was approximately $7.4 million, or $0.35 per common share, compared to approximately $5.9 million, or $0.28 per common share, in the three months ended June 30, 2022.

Liquidity and Outstanding Share Capital

As at June 30, 2023, Profound had cash of approximately $39.3 million.

As at August 9, 2023, Profound had 21,260,595 common shares issued and outstanding.

For complete financial results, please see Profound’s filings at www.sedar.com, www.sec.gov and on the Company’s website at www.profoundmedical.com under “Financial” in the Investors section.

Conference Call Details

Profound Medical is pleased to invite all interested parties to participate in a conference call today at 4:30 pm ET during which time the results will be discussed.

To participate in the conference call by telephone, please pre-register via this link to receive the dial-in number and your unique PIN.

The call will also be broadcast live and archived on the Company’s website at www.profoundmedical.com under “Webcasts” in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma. Often, but not always, forward-looking statements can be identified by the use of words such “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it will have on Profound’s operations, the demand for its products, global supply chains and economic activity in general. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen KilmerInvestor Relationsskilmer@profoundmedical.com T: 647.872.4849

Profound Medical Corp.Interim Condensed Consolidated Balance SheetsIn USD (000s)(Unaudited)

		June 30,2023$			December 31,2022$
Assets
Current assets
Cash		39,275			46,517
Trade and other receivables		6,586			6,344
Inventory		8,056			7,941
Prepaid expenses and deposits		776			1,222
Total current assets		54,693			62,024
Property and equipment		795			899
Intangible assets		592			680
Right-of-use assets		726			818
Total assets		56,806			64,421
Liabilities
Current liabilities
Accounts payable and accrued liabilities		2,424			2,091
Deferred revenue		652			471
Long-term debt		7,329			523
Derivative financial instrument		-			563
Lease liabilities		252			239
Income taxes payable		321			298
Total current liabilities		10,978			4,185
Long-term debt		-			6,651
Deferred revenue		754			764
Lease liabilities		708			817
Total liabilities		12,440			12,417
Shareholders’ Equity
Share capital		216,092			205,825
Contributed surplus		19,059			18,704
Accumulated other comprehensive income		12,673			16,837
Deficit		(203,458	)		(189,362	)
Total Shareholders’ Equity		44,366			52,004
Total Liabilities and Shareholders’ Equity		56,806			64,421

Profound Medical Corp.Interim Condensed Consolidated Statements of Loss and Comprehensive Loss/IncomeIn USD (000s)(Unaudited)

		Threemonths ended June 30,2023$		Threemonths ended June 30,2022$			SixmonthsendedJune 30,2023$		SixmonthsendedJune 30,2022$
Revenue
Recurring - non-capital		1,602		1,161			3,069		2,185
Capital equipment		-		864			393		1,204
		1,602		2,025			3,462		3,389
Cost of sales		552		1,089			1,199		2,017
Gross profit		1,050		936			2,263		1,372
Operating expenses
Research and development		3,155		3,688			6,995		6,868
General and administrative		2,080		2,632			4,186		4,978
Selling and distribution		2,251		2,394			4,356		4,596
Total operating expenses		7,486		8,714			15,537		16,442
Operating loss		6,436		7,778			13,274		15,070
Net finance costs/(income)		884		(1,864	)		739		(972	)
Loss before taxes		7,320		5,914			14,013		14,098
Income taxes		35		16			83		47
Net loss attributed to shareholders for the period		7,355		5,930			14,096		14,145
Other comprehensive (income) loss
Item that may be reclassified to loss
Foreign currency translation adjustment- net of tax		4,117		(6,181	)		4,164		(3,888	)
Net loss and comprehensive loss/(income) for the period		11,472		(251	)		18,260		10,257
Loss per share
Basic and diluted loss per common share		0.35		0.28			0.67		0.68

Profound Medical Corp.Interim Condensed Consolidated Statements of Cash FlowsIn USD (000s)(Unaudited)

	Six monthsended June 30, 2023$		Six monthsended June 30, 2022$
Operating activities
Net loss for the period	(14,096	)	(14,145	)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation of property and equipment	351		327
Amortization of intangible assets	101		531
Depreciation of right-of-use assets	108		118
Share-based compensation	1,783		2,466
Interest and accretion expense	384		32
Deferred revenue	142		11
Change in fair value of derivative financial instrument	232		(89	)
Interest income on trade and other receivables	(79	)	(212	)
Changes in non-cash working capital balances
Trade and other receivables	(27	)	(823	)
Prepaid expenses and deposits	465		636
Inventory	(191	)	(1,012	)
Accounts payable and accrued liabilities	334		(739	)
Income taxes payable	16		-
Foreign exchange on cash	(465	)	(528	)
Net cash flow used in operating activities	(10,942	)	(13,427	)
Financing activities
Repayment of long-term debt	(372	)	-
Proceeds from share options exercised	239		95
Proceeds from warrants exercised	2,423		-
Payment of lease liabilities	(146	)	(161	)
Total cash from (used in) financing activities	2,144		(66	)
Net change in cash during the period	(8,798	)	(13,493	)
Foreign exchange on cash	1,556		(424	)
Cash – Beginning of period	46,517		67,152
Cash – End of period	39,275		53,235